Search

Your search keyword '"Chung, Hyun C"' showing total 4 results
Start Over Author "Chung, Hyun C" Topic gastric cancer
4 results on '"Chung, Hyun C"'

2. Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial

Author

Fuchs, Charles S., Özgüroğlu, Mustafa, Bang, Yung-Jue, Di Bartolomeo, Maria, Mandala, Mario, Ryu, Min-Hee, Fornaro, Lorenzo, Olesinski, Tomasz, Caglevic, Christian, Chung, Hyun C., Muro, Kei, Van Cutsem, Eric, Elme, Anneli, Thuss-Patience, Peter, Chau, Ian, Ohtsu, Atsushi, Bhagia, Pooja, Wang, Anran, Shih, Chie-Schin, and Shitara, Kohei

Published
2022
Full Text
View/download PDF

4. Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design.

Author

Moehler, Markus, Ryu, Min-Hee, Dvorkin, Mikhail, Lee, Keun-Wook, Coşkun, Hasan Ş, Wong, Rachel, Chung, Hyun C, Poltoratsky, Artem, Tsuji, Akihito, Yen, Chia Jui, Muntean, Alina S, Le Sourd, Samuel, Vaccaro, Gina M, Overton, Lindsay, Boku, Narikazu, Wainberg, Zev A, Patel, Manish, Sharma, Maitreyi, Xiong, Huiling, and Conti, Ilaria

Abstract

Avelumab is a human anti-PD-L1 IgG1 monoclonal antibody that has shown antitumor activity in early phase studies in advanced/metastatic gastric/gastroesophageal junction cancer, including as first-line maintenance therapy. Here, we describe the design of JAVELIN Gastric 100 (NCT02625610), an open-label, Phase III trial. A total of 499 patients with locally advanced/metastatic HER2- gastric/gastroesophageal junction cancer adenocarcinoma, who had achieved at least stable disease following 12 weeks of first-line oxaliplatin/fluoropyrimidine chemotherapy, have been randomized 1:1 to receive avelumab maintenance therapy or continue chemotherapy. The primary objective is to demonstrate superior overall survival in all randomized patients or in the PD-L1+ population. Secondary objectives are to demonstrate superiority for progression-free survival and objective response rate, compare quality of life measures, and determine safety. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results